Poul Strange, MD, PhD

Poul Strange, MD, PhD

Poul Strange has extensive experience in the scientific and medical disciplines of the pharmaceutical industry where he has held positions ranging from drug discovery, clinical pharmacology and phase 2 and 3 clinical development through medical affairs including responsibility for biometrics and pharmacoeconomics. Data gathering, handling, analysis and reporting experience includes pre-clinical experiments, clinical pharmacology, registration trials, and medical affairs trials up to thousands of patients, health outcomes trials including patient reported outcomes, naturalistic trials, registries and retrospective analysis of large databases. He holds an M.D. and a Ph.D. in Immunology from the University of Copenhagen, as well as a Business Diploma in International Trade from Copenhagen Business School. He joined industry as a Medical Adviser for Growth Hormone in Novo Nordisk, Denmark; and has since held positions as Therapeutic Area Leader, Inflammation in ZymoGenetics, WA; various development positions in Novo Nordisk, NJ, the last one being Senior Director, Drug Development for therapeutic areas Diabetes, Coagulation Disorders, Female Health. He joined Aventis in 2000 as Therapeutic Area Leader for US Metabolism Medical Research and headed up all medical affairs activities in diabetes within the United States from year 2003 to 2006 including the time of transition from the Sanofi acquisition of Aventis. Poul Strange founded Integrated Medical Development in 2006 under its original name Poul Strange Consulting. IMD now has a Consulting as well as a CRO division.

Poul Strange peer reviewed publications

  1. Penckofer S, Quinn L, Byrn M, Ferrans C, Miller M, Strange P. Does Glycemic Variability Impact Mood and Quality of Life? Diabetes Technology & Therapeutics 2012: 1(4), 1-8.
  2. Stote R, Marbury T, Shi L, Miller M, Strange P. Enhanced Absorption of Nasulin™, an Ultrarapid-Acting Intranasal Insulin Formulation, Using Single Nostril Administration in Normal Subjects. Journal of Diabetes Science and Technology. 2011:5(1), 113-9.
  3. Stote R, Marbury T, Shi L, Miller M, Strange P. Comparison Pharmacokinetics of Two Concentrations (0.7% and 1.0%) of NasulinTM, an Ultra-Rapid-Acting Intranasal Insulin Formulation. Journal of Diabetes Science and Technology. 2010:4(3), 603-9.
  4. Dailey G, Strange P, Riddle M. Reconsideration of Severe Hypoglycemic Events in the Treat-to-Target Trial. Diabetes Technology & Therapeutics 2009; 11(8): 477-79
  5. Dailey G, Strange P. Lower severe hypoglycemia risk: insulin glargine versus NPH insulin in type 2 diabetes. Am J Manag Care. 2008: 14, 25-30.
  6. Kapitza C, Fein S, Heinemann L, Schleusener S, Levesque S, Strange P. Basal–Prandial Insulin Delivery in Type 2 Diabetes Mellitus via the V-Go™: A Novel Continuous Subcutaneous Infusion Device. Journal of Diabetes Science and Technology. 2008:2(1), 40-46.
  7. Miller M, Strange P. The Use of Fourier Models for the Analysis and Interpretation of Continuous Glucose Monitoring (CGM) Glucose Profiles. Journal of Diabetes Science and Technology. 2007:1(5), 630-638.
  8. The Disaster Response Task Force. American Diabetes Association Statement on Emergency and Disaster Preparedness. Diabetes Care. 2007; 30, 2395-8.
  9. Strange P. Treat-to-Target Insulin Titration Algorithms When Initiating Long or Intermediate Acting Insulin in Type 2 Diabetes. Journal of Diabetes Science and Technology. Volume 1, Issue 4, July 2007; 1(4): 540-548.
  10. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey D on behalf of the Insulin Glargine 4014 Study Investigators. Triple Therapy in Type 2 Diabetes: Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients. Diabetes Care 2006 29: 554-559.
  11. Kennedy L, Herman WH, Strange P, Harris A. Impact Active Versus Usual Algorithmic Titration Basal Insulin Point Care Versus Laboratory Measurement Hba1c Glycemic Control Patient Diabetes Glycemic Optimization Algorithm Lab Point Care Goal A1c Trial. Diabetes Care. 2006; 29: 1-8.
  12. Bode BW, Steed RD, Schleusener DS, Strange P. Switch Multiple Daily Injection Insulin Glargine Insulin Lispro Continuous Subcutaneous Insulin Infusion Insulin Lispro Randomized Open Label Study Continuous Glucose Monitoring System. Endocr Pract. 2005; May-Jun;11(3):157-64.
  13. Schwartz S, Sievers R, Strange P, Lyness W, Hollander P. Insulin 70/30 Mix Plus metformin Versus Triple Oral Therapy in the Treatment of Type 2 Diabetes After Failure of Two Oral Drugs. Diabetes Care. 2003; 26: 2238–2243.
  14. Mudaliar SR, Mohideen P, Baxi SC, Joyce M, Armstrong DA, Strange P, Henry RR. Pharmacodynamic and pharmacokinetic properties of a premixed 85/15 human insulin preparation. Clin Ther. 2001 Mar; 23(3): 404-12.
  15. Bode, B; Strange, P. Efficacy, Safety, and Pump Compatibility of Insulin Aspart Used in Continuous Subcutaneous Insulin Infusion Therapy in Patients with Type 1 Diabetes. Diabetes Care 2001; 24 (1): 69-72.
  16. Strange P, Goldberg RB. Repaglinide dose response? A clinician's viewpoint. Diabetes Technol Ther. 2000 Spring;2(1):119-21.
  17. Marbury TC, Ruckle JL, Hatorp V, Andersen MP, Nielsen KK, Huang WC, Strange P. Pharmacokinetics of repaglinide in subjects with renal impairment. Clin Pharmacol Ther 2000; 67 (1):7-15.
  18. Jovanovic L, Dailey G III, Huang WC, Strange P, Goldstein BJ. Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. J Clin Pharmacol 2000; 40: 49-57.
  19. Strange P, Schwartz SL, Graf RJ, Polvino W, Weston I, Marbury TC, Huang W-C; Goldberg RB. Pharmacokinetics, Pharmacodynamics, and Dose-Response Relationship of Repaglinide in Type 2 Diabetes. Diabetes Technology & Therapeutics 1999; 1(3): 247-56.
  20. Hatorp V, Won-Chin Huang W-C, Strange P. Pharmacokinetic Profiles of Repaglinide in Elderly Subjects with Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 1999; 84: 1475-1478.
  21. Mudaliar SR, Lindberg FA, Joyce M, Beerdsen P, Strange P, Lin A, Henry RR. INSULIN ASPART (B28 Asp-Insulin) - A fast-acting analogue of human insulin - Absorption kinetics and action profile compared with regular human insulin in healthy non-diabetic subjects. Diabetes Care 1999; 22 (9): 1501-6.
  22. Hatorp V, Won-Chin Huang W-C, Strange P. Repaglinide pharmacokinetics in healthy young adult and elderly subjects. Clin Ther 1999; 21(4): 702-10.
  23. Marbury T, Huang W-C, Strange P, Lebovitz H. Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res Clin Pract 1999;43(3):155-66.
  24. Goldberg RB, Einhorn D, Lucas CP, Rendell MS, Damsbo P, Huang W-C, Strange P, Brodows RG. A randomized Placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. 1998; 21: 1897-1903.
  25. Thein C, Strange P, Hansen ER, Baadsgaard O. Lesional alopecia areata T lymphocytes downregulate epithelial cell proliferation. Arch Dermatol Res. 1997; 289: 384-388.
  26. Strange P, Skov L, Lisby S, Nielsen PL, Baadsgaard O. Staphylococcal Enterotoxin B applied on normal and intact atopic skin induces dermatitis. Arch. Dermatol. 1996; 132: 27-33.
  27. Strange P, Skov L, Baadsgaard O. Interferon gamma treated keratinocytes activate T cells in the presence of superantigens: involvement of Major Histocompatibility class II molecules. J Invest Dermatol. 1994; 102: 150-104.
  28. Strange P, Cooper KD, Hansen ER, Fisher G, Larsen JK, Fox D, Krag C, Voorhees JJ, Baadsgaard O. Lesional psoriatic T-lymphocytes release growth factors that induce keratinocyte proliferation. J Invest Dermatol. 1993; 101: 695-700.
  29. Ladefoged O, Strange P, Møller A, Lam HR, Østergaard G, Larsen J-J, Arlien-Søborg P. Irreversible effects in rats of toluene (inhalation) exposure for six months. Pharmacology & Toxicology 1991; 68, 384-390.
  30. Lam H R, Larsen J-J, Ladefoged O, Møller A, Strange P, Arlien-Søborg P. Effect of 2,5-Hexanedione alone and in combination with acetone on rat behaviour, brain swelling-reaction and synaptosomal function. Neurotoxicol Teratol. 1991; 13: 407-12.
  31. Strange P, Møller A, Ladefoged O, Arlien-Søborg P. Total number and mean volume of pyramidal neocortical neurons in rats exposed to 2,5-hexanedione with and without acetone. Neurotoxicol Teratol. 1991; 13: 401-6.
  32. Møller A, Strange P, Gundersen HJG. Efficient estimation of cell volumes using the nucleator with justification of a number of efficient modifications applied in neuroscience. J Microsc. 1990; 159: 61-71.
  33. Møller A, Strange P. Mean volume, nuclear-perikaryon volume ratio and the size distribution in cortical rat neurons, estimated using the nucleator. Acta Stereol. 1989; 8/2: 345-349.